

# Jose Luis Grriz

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/2938386/jose-luis-gorriz-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

47  
papers

499  
citations

13  
h-index

21  
g-index

63  
ext. papers

889  
ext. citations

4.8  
avg, IF

4.02  
L-index

#	Paper	IF	Citations
47	Long-Term Potassium Monitoring and Dynamics in Heart Failure and Risk of Mortality. <i>Circulation</i> , <b>2018</b> , 137, 1320-1330	16.7	76
46	The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics. <i>Nephrology Dialysis Transplantation</i> , <b>2020</b> , 35, 1700-1711	4.3	52
45	Coronavirus disease 2019 in chronic kidney disease. <i>CKJ: Clinical Kidney Journal</i> , <b>2020</b> , 13, 297-306	4.5	29
44	GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	27
43	Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation and Study of Diabetic Nephropathy with Atrasentan: what was learned about the treatment of diabetic kidney disease with canagliflozin and atrasentan?. <i>CKJ: Clinical Kidney Journal</i> , <b>2019</b> , 12, 313-321	4.5	22
42	Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial. <i>European Heart Journal</i> , <b>2021</b> ,	9.5	22
41	Osteoporosis, bone mineral density and CKD-MBD complex (I): Diagnostic considerations. <i>Nefrologia</i> , <b>2018</b> , 38, 476-490	1.5	20
40	An in-depth analysis shows a hidden atherogenic lipoprotein profile in non-diabetic chronic kidney disease patients. <i>Expert Opinion on Therapeutic Targets</i> , <b>2019</b> , 23, 619-630	6.4	18
39	Osteoporosis, bone mineral density and CKD-MBD (II): Therapeutic implications. <i>Nefrologia</i> , <b>2019</b> , 39, 227-242	1.5	16
38	Exploring Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors for Organ Protection in COVID-19. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	14
37	Early effects of empagliflozin on exercise tolerance in patients with heart failure: A pilot study. <i>Clinical Cardiology</i> , <b>2018</b> , 41, 476-480	3.3	14
36	Diabetic Kidney Disease and COVID-19: The Crash of Two Pandemics. <i>Frontiers in Medicine</i> , <b>2020</b> , 7, 199	4.9	14
35	Sodium-glucose cotransporter 2 inhibition: towards an indication to treat diabetic kidney disease. <i>Nephrology Dialysis Transplantation</i> , <b>2020</b> , 35, i13-i23	4.3	13
34	Epicardial Adipose Tissue, Adiponectin and Leptin: A Potential Source of Cardiovascular Risk in Chronic Kidney Disease. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	13
33	Nephroprotection by Hypoglycemic Agents: Do We Have Supporting Data?. <i>Journal of Clinical Medicine</i> , <b>2015</b> , 4, 1866-89	5.1	13
32	Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2021</b> , 32, 2352-2361	12.7	13
31	Atrial fibrillation and chronic kidney disease: focus on rivaroxaban. <i>Journal of Comparative Effectiveness Research</i> , <b>2015</b> , 4, 651-64	2.1	12

30	IgA-Dominant Infection-Associated Glomerulonephritis Following SARS-CoV-2 Infection. <i>Viruses</i> , <b>2021</b> , 13,	6.2	9
29	Safety and immediate humoral response of COVID-19 vaccines in chronic kidney disease patients: the SENCOVAC study. <i>Nephrology Dialysis Transplantation</i> , <b>2021</b> ,	4.3	8
28	Renal function dynamics following co-administration of sacubitril/valsartan and empagliflozin in patients with heart failure and type 2 diabetes. <i>ESC Heart Failure</i> , <b>2020</b> , 7, 3792	3.7	5
27	CA125 but not NT-proBNP predicts the presence of a congestive intrarenal venous flow in patients with acute heart failure. <i>European Heart Journal: Acute Cardiovascular Care</i> , <b>2021</b> , 10, 475-483	4.3	5
26	Kidneys also speak Spanish. <i>Nefrologia</i> , <b>2021</b> , 41, 225-226	1.5	4
25	Dynamic assessment of interleukin-6 during hemodialysis and mortality in coronavirus disease-19. <i>Therapeutic Apheresis and Dialysis</i> , <b>2021</b> , 25, 908-916	1.9	4
24	Review of the renal endpoints used in cardiovascular safety clinical trials in type 2 diabetes mellitus patients and their importance in primary care. <i>Primary Care Diabetes</i> , <b>2019</b> , 13, 485-494	2.4	3
23	Prevalence of Vertebral Fractures and Their Prognostic Significance in the Survival in Patients with Chronic Kidney Disease Stages 3-5 Not on Dialysis. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	3
22	Iron replacement therapy in the management of anaemia in non-dialysis chronic renal failure patients: Perspective of the Spanish Nephrology Society Anaemia Group. <i>Nefrologia</i> , <b>2021</b> , 41, 123-136	1.5	3
21	Cardiorenal Fat: A Cardiovascular Risk Factor With Implications in Chronic Kidney Disease. <i>Frontiers in Medicine</i> , <b>2021</b> , 8, 640814	4.9	3
20	P1003STUDY DESIGN OF THE ROTATION FOR OPTIMAL TARGETING OF ALBUMINURIA AND TREATMENT EVALUATION (ROTATE-3): A ROTATION STUDY OF DIFFERENT ALBUMINURIA LOWERING DRUGS CLASSES TO STUDY INDIVIDUAL DRUG RESPONSE IN DIABETIC AND NON-DIABETIC CKD. <i>Nephrology Dialysis Transplantation</i> , <b>2020</b> , 35,	4.3	2
19	Refractory congestive heart failure: when the solution is outside the heart. <i>ESC Heart Failure</i> , <b>2020</b> , 7, 311-314	3.7	2
18	Insulin Withdrawal in Diabetic Kidney Disease: What Are We Waiting for?. <i>International Journal of Environmental Research and Public Health</i> , <b>2021</b> , 18,	4.6	2
17	Oxidative Stress in Non-Dialysis-Dependent Chronic Kidney Disease Patients. <i>International Journal of Environmental Research and Public Health</i> , <b>2021</b> , 18,	4.6	2
16	LONG-TERM MORTALITY AND TRAJECTORY OF POTASSIUM MEASUREMENTS FOLLOWING AN EPISODE OF ACUTE SEVERE HYPERKALEMIA. <i>Nephrology Dialysis Transplantation</i> , <b>2021</b> ,	4.3	2
15	The Sick Adipose Tissue: New Insights Into Defective Signaling and Crosstalk With the Myocardium. <i>Frontiers in Endocrinology</i> , <b>2021</b> , 12, 735070	5.7	2
14	The Place and Value of Sodium-Glucose Cotransporter 2 Inhibitors in the Evolving Treatment Paradigm for Type 2 Diabetes Mellitus: A Narrative Review.. <i>Diabetes Therapy</i> , <b>2022</b> , 13, 847	3.6	2
13	In response to the paper \$High-protein diet: A barrier to the nephroprotective effects of sodium-glucose co-transporter-2 inhibitors?\$ <i>Diabetes, Obesity and Metabolism</i> , <b>2020</b> , 22, 1701-1702	6.7	1

12	Efficacy and safety of the PCSK9 inhibitors in the treatment of dyslipidemia in chronic kidney disease. <i>Nefrologia</i> , <b>2020</b> , 40, 499-505	1.5	1
11	Cost of Type 2 Diabetes Patients with Chronic Kidney Disease Based on Real-World Data: An Observational Population-Based Study in Spain. <i>International Journal of Environmental Research and Public Health</i> , <b>2021</b> , 18,	4.6	1
10	Prognostic value of NT-proBNP and CA125 across glomerular filtration rate categories in acute heart failure. <i>European Journal of Internal Medicine</i> , <b>2021</b> ,	3.9	1
9	Finerenone: A Potential Treatment for Patients with Chronic Kidney Disease and Type 2 Diabetes Mellitus.. <i>European Endocrinology</i> , <b>2021</b> , 17, 84-87	3.4	0
8	Cardiovascular risk factors and the impact on prognosis in patients with chronic kidney disease secondary to autosomal dominant polycystic kidney disease. <i>BMC Nephrology</i> , <b>2021</b> , 22, 110	2.7	0
7	Urinary Dickkopf-3: a new biomarker for CKD progression and mortality. <i>Nephrology Dialysis Transplantation</i> , <b>2021</b> , 36, 2199-2207	4.3	0
6	Kidneys also speak Spanish: Initiatives towards standardisation of our nephrology nomenclature. <i>Nefrologia</i> , <b>2021</b> , 42, 223-223	1.5	0
5	Large Between-Patient Variability in eGFR Decline before Clinical Trial Enrollment and Impact on Atrasentan's Efficacy: A Analysis from the SONAR Trial. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2021</b> , 32, 2731-2734	12.7	0
4	Antithrombotic Therapy in Elderly Patients with Acute Coronary Syndromes. <i>Journal of Clinical Medicine</i> , <b>2022</b> , 11, 3008	5.1	0
3	Survival with low- and high-flux dialysis. <i>CKJ: Clinical Kidney Journal</i> , <b>2021</b> , 14, 1915-1923	4.5	
2	Letter by Escobar et al Regarding Article, "On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin: Insights From ROCKET AF". <i>Circulation</i> , <b>2016</b> , 134, e530-e531	16.7	
1	Rivaroxaban Inappropriate Dosage Predictor Factors Using The Ckd-Epi Equation. <i>Nefrologia</i> , <b>2021</b> , 41, 216-218	1.5	